1. Home
  2. CCHH vs APRE Comparison

CCHH vs APRE Comparison

Compare CCHH & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CCHH

CCH Holdings Ltd Ordinary Shares

N/A

Current Price

$0.40

Market Cap

10.2M

Sector

N/A

ML Signal

N/A

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.94

Market Cap

12.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCHH
APRE
Founded
2015
2006
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2M
12.1M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
CCHH
APRE
Price
$0.40
$0.94
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
69.6K
241.1K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$43.55
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.55
52 Week High
$15.39
$2.22

Technical Indicators

Market Signals
Indicator
CCHH
APRE
Relative Strength Index (RSI) 33.30 56.57
Support Level $0.36 $0.90
Resistance Level $0.68 $1.01
Average True Range (ATR) 0.04 0.08
MACD -0.00 0.00
Stochastic Oscillator 7.37 57.72

Price Performance

Historical Comparison
CCHH
APRE

About CCHH CCH Holdings Ltd Ordinary Shares

CCH Holdings Ltd operates a hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot, mainly under two brand, namely Chicken Claypot House and Zi Wei Yuan, owned by the wholly owned subsidiaries of the Company. The Company conducts its operations through its wholly owned subsidiaries in Malaysia and is engaged as a restaurant operator, licensor and loyalty owner, and general trader. Currently, the Group has developed a restaurant chain including approximately 15 company-owned restaurant outlets, 13 franchised restaurant outlets in Malaysia, and 4 franchised restaurant outlets outside Malaysia.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: